References
- Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol 2017;3:602-609. https://doi.org/10.1001/jamaoncol.2016.5751
- Xu Z, Huo X, Tang C, Ye H, Nandakumar V, Lou F, et al. Frequent KIT mutations in human gastrointestinal stromal tumors. Sci Rep 2014;4:5907. https://doi.org/10.1038/srep05907
- Fisher KE, Zhang L, Wang J, Smith GH, Newman S, Schneider TM, et al. Clinical validation and implementation of a targeted next-generation sequencing assay to detect somatic variants in non-small cell lung, melanoma, and gastrointestinal malignancies. J Mol Diagn 2016;18:299-315. https://doi.org/10.1016/j.jmoldx.2015.11.006
- Hamblin A, Wordsworth S, Fermont JM, Page S, Kaur K, Camps C, et al. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service. PLoS Med 2017;14:e1002230. https://doi.org/10.1371/journal.pmed.1002230
- Giardina T, Robinson C, Grieu-Iacopetta F, Millward M, Iacopetta B, Spagnolo D, et al. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice. Pathology 2018;50:389-401.
- Shahsiah R, DeKoning J, Samie S, Latifzadeh SZ, Kashi ZM. Validation of a next generation sequencing panel for detection of hotspot cancer mutations in a clinical laboratory. Pathol Res Pract 2017;213:98-105. https://doi.org/10.1016/j.prp.2016.11.016
-
Williams HL, Walsh K, Diamond A, Oniscu A, Deans ZC. Validation of the
$Oncomine^{TM}$ focus panel for next-generation sequencing of clinical tumour samples. Virchows Arch 2018;473:489-503. https://doi.org/10.1007/s00428-018-2411-4 - Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465. https://doi.org/10.1053/hupa.2002.123545
- Jones RL. Practical aspects of risk assessment in gastrointestinal stromal tumors. J Gastrointest Cancer 2014;45:262-267. https://doi.org/10.1007/s12029-014-9615-x
- 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature 2015;526:68-74. https://doi.org/10.1038/nature15393
- Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, et al. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med 2016;14:339. https://doi.org/10.1186/s12967-016-1075-6
- Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol 2017;13:93-107. https://doi.org/10.2217/fon-2016-0192
- Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 2012;63:247-258. https://doi.org/10.1146/annurev-med-043010-091813
- Mayr P, Markl B, Agaimy A, Kriening B, Dintner S, Schenkirsch G, et al. Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA. Langenbecks Arch Surg 2019;404:605-613. https://doi.org/10.1007/s00423-019-01773-2
- Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int 2015;65:9-18. https://doi.org/10.1111/pin.12230
- Mei L, Du W, Idowu M, von Mehren M, Boikos SA. Advances and challenges on management of gastrointestinal stromal tumors. Front Oncol 2018;8:135. https://doi.org/10.3389/fonc.2018.00135
- Charville GW, Longacre TA. Surgical pathology of gastrointestinal stromal tumors: practical implications of morphologic and molecular heterogeneity for precision medicine. Adv Anat Pathol 2017;24:336-353. https://doi.org/10.1097/PAP.0000000000000166
- El-Menyar A, Mekkodathil A, Al-Thani H. Diagnosis and management of gastrointestinal stromal tumors: an up-to-date literature review. J Cancer Res Ther 2017;13:889-900.
- Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580. https://doi.org/10.1126/science.279.5350.577
- Chen LL, Holden JA, Choi H, Zhu J, Wu EF, Jones KA, et al. Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. Mod Pathol 2008;21:826-836. https://doi.org/10.1038/modpathol.2008.46
- Sciot R, Debiec-Rychter M, Daugaard S, Fisher C, Collin F, van Glabbeke M, et al. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): an analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. Eur J Cancer 2008;44:1855-1860. https://doi.org/10.1016/j.ejca.2008.06.003
- Wozniak A, Rutkowski P, Schoffski P, Ray-Coquard I, Hostein I, Schildhaus HU, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST. Clin Cancer Res 2014;20:6105-6116. https://doi.org/10.1158/1078-0432.CCR-14-1677
- Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 2006;23:91-102. https://doi.org/10.1053/j.semdp.2006.08.006
- Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 2006;86:94-100. https://doi.org/10.1038/labinvest.3700360
- Lasota J, Felisiak-Golabek A, Wasag B, Kowalik A, Zieba S, Chlopek M, et al. Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases. Mod Pathol 2016;29:275-282. https://doi.org/10.1038/modpathol.2015.160
- Tornillo L, Duchini G, Carafa V, Lugli A, Dirnhofer S, Di Vizio D, et al. Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest 2005;85:921-931. https://doi.org/10.1038/labinvest.3700284
- Lopes LF, Bacchi CE. EGFR and gastrointestinal stromal tumor: an immunohistochemical and FISH study of 82 cases. Mod Pathol 2007;20:990-994. https://doi.org/10.1038/modpathol.3800932
- Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016;2:922-928. https://doi.org/10.1001/jamaoncol.2016.0256
- Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349. https://doi.org/10.1200/jco.2003.04.190
- Gopie P, Mei L, Faber AC, Grossman SR, Smith SC, Boikos SA. Classification of gastrointestinal stromal tumor syndromes. Endocr Relat Cancer 2018;25:R49-R58. https://doi.org/10.1530/ERC-17-0329
- Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28:1247-1253. https://doi.org/10.1200/JCO.2009.24.2099
- Cai H, Jing C, Chang X, Ding D, Han T, Yang J, et al. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing. J Transl Med 2019;17:189. https://doi.org/10.1186/s12967-019-1941-0
- Luthra R, Patel KP, Routbort MJ, Broaddus RR, Yau J, Simien C, et al. A Targeted high-throughput next-generation sequencing panel for clinical screening of mutations, gene amplifications, and fusions in solid tumors. J Mol Diagn 2017;19:255-264. https://doi.org/10.1016/j.jmoldx.2016.09.011
- Dudley JC, Gurda GT, Tseng LH, Anderson DA, Chen G, Taube JM, et al. Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma. Mol Diagn Ther 2014;18:409-418. https://doi.org/10.1007/s40291-014-0091-6
Cited by
- MicroRNA-1249 Targets G Protein Subunit Alpha 11 and Facilitates Gastric Cancer Cell Proliferation, Motility and Represses Cell Apoptosis vol.14, 2020, https://doi.org/10.2147/ott.s272599